Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

bluefish pharmaceuticals ab - hydroklortiazid - tablett - 12,5 mg - hydroklortiazid 12,5 mg aktiv substans; laktosmonohydrat hjälpämne

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

bluefish pharmaceuticals ab - hydroklortiazid - tablett - 25 mg - hydroklortiazid 25 mg aktiv substans; laktosmonohydrat hjälpämne

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

sun pharmaceutical industries europe b.v. - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - mannitol hjälpämne; azacitidin 25 mg aktiv substans

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

uni-pharma kleon tsetis pharmaceutical laboratories s.a. - dexametasonnatriumfosfat - Ögondroppar, lösning i endosbehållare - 1 mg/ml - dexametasonnatriumfosfat 1,093 mg aktiv substans

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

prothya biosolutions netherlands b.v - immunglobulin, humant normalt, för intravenös administrering - infusionsvätska, lösning - 100 mg/ml - glukosmonohydrat hjälpämne; immunglobulin, humant normalt, för intravenös administrering 100 mg aktiv substans

Ευρωπαϊκή Ένωση - Σουηδικά - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doxorubicinhydroklorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiska medel - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

sun pharmaceutical industries europe b.v. - ciprofloxacinhydroklorid (monohydrat) - filmdragerad tablett - 500 mg - ciprofloxacinhydroklorid (monohydrat) 594,14 mg aktiv substans - ciprofloxacin

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

jubilant pharmaceuticals nv - valsartan - filmdragerad tablett - 160 mg - laktos (vattenfri) hjälpämne; valsartan 160 mg aktiv substans - valsartan

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

jubilant pharmaceuticals nv - valsartan - filmdragerad tablett - 40 mg - valsartan 40 mg aktiv substans; laktos (vattenfri) hjälpämne - valsartan

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

jubilant pharmaceuticals nv - valsartan - filmdragerad tablett - 80 mg - laktos (vattenfri) hjälpämne; valsartan 80 mg aktiv substans - valsartan